Table 1.
Characteristic | High‐Intensity Statin Therapy, n = 229 437 | Low‐ to Moderate‐Intensity Statin Therapy, n = 399 568 | P Value |
---|---|---|---|
Age, y, mean/SD | 68.8/9.7 | 72/10.5 | <0.0001 |
Female sex, n (%) | 2828 (1.23) | 4868 (1.22) | 0.60 |
Race, n (%) | |||
White | 196 006 (85.4) | 348 733 (87.3) | |
Black | 20 833 (9.1) | 32 051 (8.0) | |
Other | 3944 (1.7) | 6610 (1.6) | |
Unknown | 8654 (3.8) | 12 174 (3.1) | <0.0001 |
DM, n (%) | 110 405 (48.1) | 399 568 (63.5) | <0.0001 |
Hypertension, n (%) | 191 636 (83.5) | 331 630 (83) | <0.0001 |
History of CHD, n (%)a | 220 562 (96.1) | 377 380 (94.4) | <0.0001 |
History of MI, n (%) | 104 843 (45.7) | 172 050 (43.1) | <0.0001 |
History of PAD only, n (%) | 8875 (3.9) | 22 188 (5.5) | <0.0001 |
Diagnostic Cost Group RRS, mean/SD | 1.77/2.52 | 1.94/2.85 | <0.0001 |
Receiving primary care from a physician provider, n (%)b | 173 851 (78) | 300 610 (77.5) | <0.0001 |
Receiving care at a teaching facility | 96 939 (42.3) | 166 728 (41.7) | <0.0001 |
Number of primary‐care visits in prior 12 months, mean/SD | 4.89/4 | 4.86/4 | 0.006 |
Receiving nonstatin lipid‐lowering medication(s), n (%)c | 36 434 (15.9) | 44 037 (11) | <0.0001 |
Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease; DM, diabetes mellitus; MI, myocardial infarction; PAD, peripheral artery disease; RRS, relative risk score; SD, standard deviation.
History of CHD with or without PAD.
Percentage calculated from among those with available data.
Nonstatin lipid‐lowering medications include bile acid sequestrants, ezetimibe, niacin therapy, fish oil, or fibrate use.